loader image





Funding: European Regional Development Fund (ERDF), Measure 1.2.1. Specific support goal “To Increase the Private Sector Investments R&D”; measure “Support for Improvement of Technology Transfer System” “Industry‑Driven Research”

Project Title: „Plant virus-derived vaccine technology platform”

Project No.: KC-PI-2017/83

Technical and economic feasibility study and the development of commercialisation strategy that will be accomplished within the first 6 months (30 th January 2017 – 29 th July 2018)

Technical and economic feasibility study and the development of commercialisation strategy costs: 27 777,77 EUR

Principle Investigator: Dr. biol. A.Zeltiņš

The aim of the project is the development of vaccine platform, based on plant virus-like particles (VLPs). These platform VLPs will serve as a core component of various prophylactic and therapeutic vaccines.

To create a new plant VLP vaccine platform for a variety of vaccines, first, the plant VLPs containing strong T-cell epitopes potentially stimulating T-cell activity will be found using databases available in Internet (eg., www.iedb.org). The VLP candidates for platform development will be selected from plant VLPs, which are constructed during previous projects. If necessary, new plant VLP candidates will be obtained using gene synthesis, expression in recombinant micro-organisms and subsequent purification. Plant VLPs will be characterized by physical and chemical methods, as well as in mouse immunization experiments. Furthermore, most promising plant VLP will be tested in experiments with donor blood cells to select plant VLPs, which are capable of stimulating human immune cells. VLPs with the most suitable properties will serve as a platform for the creation of a variety of vaccines.

During the 1st phase of the project, a technical and economic feasibility study and commercialisation strategy will be developed.

Information published 30.01.2018.


In the period from 30.01.2018-30.04.2018 the procurement regulations for procurement “Feasibility study and commercialization strategy development service ” were prepared. The purpose of the service is to define the steps to develop a product or technology from conception to market introduction, and also to analyse the choice of a more advantageous solution between assigning the right to use industrial property to another person (licensing agreement, patent sale) or creating a new business on a scientific basis, and make recommendation what information should be prepared to get potential licensees or investment funds attention and offer them the technology. The above-mentioned procurement was announced on the website of the Procurement Monitoring Bureau on 20.03.2018.

KPMG Baltics Ltd. was recognized as the winner in the procurement.

Information published 27.04.2018.


During the reporting period continue work to the development of the Technically Economic feasibility study and the Commercialisation strategy with “KPMG Baltics”.

Published 30.07.2018.